We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Glutamate Inhibitors Protect Against Nerve Damage in Huntington's

By Biotechdaily staff writers
Posted on 14 Nov 2006
Researchers working with mouse brain cells growing in tissue culture have found evidence that supports the potential use of the glutamate pathway inhibitors memantine and riluzole for treatment of Huntington's disease (HD).

Glutamate is the most abundant fast, excitatory neurotransmitter in the mammalian nervous system. More...
At chemical synapses, glutamate is stored in vesicles until nerve impulses trigger its release from the pre-synaptic cell. In the opposing post-synaptic cell, glutamate receptors, such as the NMDA receptor, bind glutamate and are activated. Because of its role in synaptic plasticity, it is believed that glutamate is involved in cognitive functions such as learning and memory in the brain.

HD affects the brain striatum, which is involved in the control of movement and of "executive function,” or planning and abstract thinking. It primarily attacks the striatal medium spiny neurons, the main component of the striatum. Previous research had shown that dysregulation of the glutamate/calcium signaling pathway was a possible cause of striatal neurodegeneration in HD.

In the current study, investigators at the University of Texas Southwestern Medical Center (Dallas, USA) worked with cultured mouse striatal spiny neurons to determine the capability of five clinically relevant glutamate pathway inhibitors to protect against damage caused by HD.

Results published in the October 30, 2006, issue of Neuroscience Letters revealed that folic acid, gabapentin, and lamotrigine did not protect HD neurons from glutamate-induced cell death, but memantine and riluzole were protective. These findings were interpreted as supporting the potential use of memantine and riluzole for treatment of HD.

"We systematically and quantititatively tested the clinically relevant drugs side-by-side in the same HD model. That has never been done before,” said senior author Dr. Ilya Bezprozvanny, associate professor of physiology at the University of Texas Southwestern Medical Center. "Our results provide the first systematic comparison of various clinically relevant glutamate pathway inhibitors for HD treatment and indicate that memantine holds the most promise based on its in vitro efficacy. Whole animal studies of memantine in an HD mouse model will be required to validate these findings.”



Related Links:
University of Texas Southwestern Medical Center

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Pipette Controller
Sapphire MaxiPette
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.